Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Psychedelic drug MDMA moves closer to US approval following success in PTSD trial

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

doi: https://doi.org/10.1038/d41586-023-02886-x

Updates & Corrections

  • Correction 15 September 2023: An earlier version of this story incorrectly said that the American Psychological Association has urged caution over MDMA, stating that there has been a lack of evidence to endorse its use outside of controlled trials. It was the American Psychiatric Association.

References

  1. Mitchell, J. M. et al. Nature Med. 27, 1025–1033 (2021).

    Article  PubMed  Google Scholar 

  2. Mitchell, J. M. et al. Nature Med. https://doi.org/10.1038/s41591-023-02565-4 (2023).

    Article  Google Scholar 

  3. Schnurr, P. P. et al. JAMA Netw. Open 5, e2136921 (2022).

    Article  Google Scholar 

Download references

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Quick links